Jonathan W. Riess

UC Davis Comprehensive Cancer Center

Medicine · Health Sciences

43h-index13.8kcitations524works7.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(234), Colorectal Cancer Treatments and Studies(125), Lung Cancer Research Studies(85), Cancer Genomics and Diagnostics(72), RNA modifications and cancer(57)

Publications515 total

289 COPERNICUS: A Multinational Pragmatic Phase 2 Trial of Subcutaneous (SC) Amivantamab (Ami) in Common EGFR-Mutated (cEGFRm) NSCLC
Lung Cancer·2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in <i>RET</i> -Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Clinical Cancer Research·2026Open Access
Supplementary Figure S6 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S3 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S8 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S1 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S1 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S3 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S4 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S4 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S9 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S5 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S7 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S2 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S10 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S6 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S5 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S2 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Tables1 from The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
2025Open Access
Suppl Figures 1 from The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
2025Open Access
page 1 of 26Next →

Frequent Co-authors

Heather A. Wakelee(12), David R. Gandara(10), Matthew A. Gubens(9), Collin M. Blakely(9), Joel W. Neal(9), Philip C. Mack(8), Trever G. Bivona(8), Caroline E. McCoach(7), Dara L. Aisner(6), Julia Rotow(6), Robert C. Doebele(6), Mark M. Awad(6), Billy W. Loo(5), Christine M. Lovly(5), Sandip Pravin Patel(5), Nir Peled(5), Julie R. Brahmer(5), Justin F. Gainor(5), Pasi A. Jänne(5), Sukhmani K. Padda(5)